Altimmune ( ($ALT) ) has released its Q2 earnings. Here is a breakdown of the information Altimmune presented to its investors. Altimmune, Inc. is ...

Below are the transcripts from the Q2 earnings call. This transcript is brought to you by Benzinga APIs. For real-time access ...

Altimmune (NASDAQ:ALT) shares rose on Tuesday after the company reported promising Q2 results banking on its experimental candidate, pemvidutide. Pemvidutide is in development for the treatment of ...

GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic ...

--Altimmune, Inc., a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced financial results for the ...

Altimmune Shares Rise on Liver Disease Trial Data Presentation Published: June 26, 2025 at 6:16 a.m. ET Share Resize ...

Altimmune, Inc.'s top-line data from the phase 2b IMPACT study using pemvidutide for the treatment of patients with MASH expected in Q2 of 2025. The global non-alcoholic steatohepatitis [NASH ...

--Altimmune, Inc., a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the Company ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease.

By Connor Hart Shares of Altimmune tumbled after the company failed to achieve statistical significance on one of the dual primary endpoints in a recent trial evaluating its drug, pemvidutide, for ...

Altimmune shares jumped 8.5% on Friday. The stock is higher ahead of next week's presentation at the European Association for the Study of the Liver International Liver Congress.